logo
logo

Viecure Announces $25 Million Series A Investment Led By Northpond Ventures To Improve Oncology Care, Scale A.I. And Patient-Focused Technologies

Apr 20, 2021•about 4 years ago

Amount Raised

$25 Million

Round Type

series a

Denver

Description

VieCure, Inc. today announced the closing of its $25 million Series A growth equity investment, led by Northpond Ventures. An undisclosed investor is also contributing to the round. VieCure, an oncology clinical informatics company with an artificial intelligence (AI) enabled clinical decision support platform, will use the new funding to accelerate the deployment of its next generation clinical decision support solution, and grow the sales and business development organization in response to the expanding pipeline and partnering opportunities in the life sciences arena

Company Information

Company

Vie Cure

Location

Denver, Colorado, United States

About

VieCure has developed a proprietary artificial intelligence informatics software platform in conjunction with a clinical inference engine and smart electronic medical record in oncology. The VieCure™ platform is a real-time decision support system that combines clinical knowledge with patient data to assist oncologists and hematologists in generating personalized treatment plans and managing a patient's treatment throughout diagnosis, cancer therapy, and ongoing follow-up care. VieCure is contracted with cancer centers in the United States, Bahamas, and Antigua and has forged meaningful strategic alliances with global pharmaceutical, molecular diagnostic, and laboratory companies.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech